EVAX
Evaxion Biotech A/S [EVAX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EVAX Stock Summary
Top 10 Correlated ETFs
EVAX
Top 10 Correlated Stocks
EVAX
In the News
EVAX Financial details
Company Rating
-
Market Cap
15.54M
Income
-22.16M
Revenue
73.6K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-0.81
Forward P/E
-
PEG
0.51
P/S
-
P/B
-0.22
P/C
-
P/FCF
1.52
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.24
EPS next Y
-
EPS next Q
-
EPS this Y
-17.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-18.54%
-
-
-
-
SMA20
50%
SMA50
50%
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
33%
ROE
41%
ROC
0.32%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.824-18.5
52W High
-83.81%
52W Low
+45.71%
RSI
68
Rel Volume
0.09
Avg Volume
701.1K
Volume
61.79K
Perf Week
6.35%
Perf Month
90.46%
Perf Quarter
-39.04%
Perf Half Y
-55.85%
-
-
-
-
Beta
-0.016
-
-
Volatility
0.17%, 0.59%
Prev Close
-3.51%
Price
2.9141
Change
-4.77%
Company Profile
- Volume Average 701.1K
- Market Capitalization 15.54M
- Employee 63
- CEO Mr. Christian Kanstrup M.Sc.
- Headquarters Horsholm,DK
- IPO Date 2021-02-05
-
Website
https://www.evaxion-biotech.com 
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
